The role of obesity in cardiomyopathy and nephropathy

Current Pharmaceutical Design

Volumn 20, Issue 9, 2014, Pages 1409-1417

  Tiwari, Shuchita ^a   Ndisang, Joseph Fomusi ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Aldosterone; Angiotensin; Cardiomyopathy; Inflammation; Nephropathy; Nuclear factor kappa B; Oxidative stress; Toll like receptor 4

Indexed keywords

ADIPOSE TISSUE; CARDIOMYOPATHY; ENDOTHELIAL DYSFUNCTION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; KIDNEY DISEASE; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; ANIMAL; CARDIOMYOPATHIES; COMPLICATION; KIDNEY DISEASES; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

AUTACOID; CYTOKINE;

ANIMALS; CARDIOMYOPATHIES; CYTOKINES; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; KIDNEY DISEASES; OBESITY; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 84896382372     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990562     Document Type: Review

References (203)

1. Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab 2008; 93: S9-30.
2. Danaei G, Ding EL, Mozaffarian D, et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med 2009; 6: e1000058.
3. Lin CH, Chou CY, Lin CC, Huang CC, Liu CS, Lai SW. Waist-toheight ratio is the best index of obesity in association with chronic kidney disease. Nutrition 2007; 23: 788-93.
4. Chrysant SG, Chrysant GS. New insights into the true nature of the obesity paradox and the lower cardiovascular risk. J Am Soc Hypertens 2013; 7: 85-94.
5. Mandavia CH, Pulakat L, DeMarco V, Sowers JR. Over-nutrition and metabolic cardiomyopathy. Metabolism 2012; 61: 1205-10.
6. Reisin E, Jack AV. Obesity and hypertension: mechanisms, cardiorenal consequences, and therapeutic approaches. Med Clin North Am 2009; 93: 733-51.
7. Goldfine AB, Fonseca V, Shoelson SE. Therapeutic approaches to target inflammation in type 2 diabetes. Clin Chem 2011; 57: 162-7.
8. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-801.
9. Taube A, Schlich R, Sell H, Eckardt K, Eckel J. Inflammation and metabolic dysfunction: links to cardiovascular diseases. Am J Physiol Heart Circ Physiol 2012; 302: H2148-65.
10. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest 2011; 121: 2111-7.
11. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-9.
12. Manabe I. Chronic inflammation links cardiovascular, metabolic and renal diseases. Circ J 2011; 75: 2739-48.
13. Haines DD, Lekli I, Teissier P, Bak I, Tosaki A. Role of haeme oxygenase-1 in resolution of oxidative stress-related pathologies: focus on cardiovascular, lung, neurological and kidney disorders. Acta Physiol (Oxf) 2012; 204: 487-501.
14. Jadhav A, Tiwari S, Lee P, Ndisang JF. The heme oxygenase system selectively enhances the anti-inflammatory macrophage-m2 phenotype, reduces pericardial adiposity, and ameliorated cardiac injury in diabetic cardiomyopathy in zucker diabetic Fatty rats. J Pharmacol Exp Ther 2013; 345: 239-49.
15. Ndisang JF, Jadhav A. Hemin therapy suppresses inflammation and retroperitoneal adipocyte hypertrophy to improve glucose metabolism in obese rats co-morbid with insulin resistant type-2 diabetes. Diabetes Obes Metab 2013; 15: 1029-39.
16. Takahashi K, Yamaguchi S, Shimoyama T, et al. JNK-and IkappaB-dependent pathways regulate MCP-1 but not adiponectin release from artificially hypertrophied 3T3-L1 adipocytes preloaded with palmitate in vitro. Am J Physiol Endocrinol Metab 2008; 294: E898-909.
17. Yeop Han C, Kargi AY, Omer M, et al. Differential effect of saturated and unsaturated free fatty acids on the generation of monocyte adhesion and chemotactic factors by adipocytes: dissociation of adipocyte hypertrophy from inflammation. Diabetes 2010; 59: 386-96.
18. Ndisang JF. Role of heme oxygenase in inflammation, insulinsignalling, diabetes and obesity. Mediators Inflamm 2010; 2010: 359732.
19. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007; 447: 1116-20.
20. Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306: 457-61.
21. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha-and obesity-induced insulin resistance. Science 1996; 271: 665-8.
22. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 1994; 94: 1543-9.
23. Klover PJ, Clementi AH, Mooney RA. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 2005; 146: 3417-27.
24. Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003; 52: 2784-9.
25. Kanemaki T, Kitade H, Kaibori M, et al. Interleukin 1beta and interleukin 6, but not tumor necrosis factor alpha, inhibit insulinstimulated glycogen synthesis in rat hepatocytes. Hepatology 1998; 27: 1296-303.
26. Ma LJ, Mao SL, Taylor KL, et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004; 53: 336-46.
27. Li DJ, Evans RG, Yang ZW, et al. Dysfunction of the cholinergic anti-inflammatory pathway mediates organ damage in hypertension. Hypertension 2011; 57: 298-307.
28. Niu J, Wang K, Kolattukudy PE. Cerium oxide nanoparticles inhibit oxidative stress and nuclear factor-kappaB activation in H9c2 cardiomyocytes exposed to cigarette smoke extract. J Pharmacol Exp Ther 2011; 338: 53-61.
29. Consoli C, Gatta L, Iellamo F, Molinari F, Rosano GM, Marlier LN. Severity of left ventricular dysfunction in heart failure patients affects the degree of serum-induced cardiomyocyte apoptosis. Importance of inflammatory response and metabolism. Int J Cardiol 2012.
30. Vlahakos D, Arkadopoulos N, Kostopanagiotou G, et al. Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers renoprotection after acute hepatic ischemia in pigs. Artif Organs 2012; 36: 400-8.
31. Ascon M, Ascon DB, Liu M, et al. Renal ischemia-reperfusion leads to long term infiltration of activated and effector-memory T lymphocytes. Kidney Int 2009; 75: 526-35.
32. Song MJ, Kim KH, Yoon JM, Kim JB. Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem Biophys Res Commun 2006; 346: 739-45.
33. Amdekar S, Singh V, Singh DD. Probiotic therapy: immunomodulating approach toward urinary tract infection. Curr Microbiol 2011; 63: 484-90.
34. Li X, Meng Y, Wu P, Zhang Z, Yang X. Angiotensin II and Aldosterone stimulating NF-kappaB and AP-1 activation in hepatic fibrosis of rat. Regul Pept 2007; 138: 15-25.
35. Otani H, Otsuka F, Inagaki K, et al. Antagonistic effects of bone morphogenetic protein-4 and-7 on renal mesangial cell proliferation induced by aldosterone through MAPK activation. Am J Physiol Renal Physiol 2007; 292: F1513-25.
36. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, et al. Loss-offunction mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 2007; 56: 1986-98.
37. Tanguy S, Toufektsian MC, Grauzam S, et al. Cardiac dysfunction in rats with dietary-induced insulin resistance associated with pharmacologically-induced dyslipidemia. Curr Pharm Des 2013.
38. Fiorentino TV, Prioletta A, Zuo P, Folli F. Hyperglycemia-induced Oxidative stress and its Role in Diabetes Mellitus related Cardiovascular Diseases. Curr Pharm Des 2013.
39. Yan Z, Ni Y, Wang P, et al. Peroxisome proliferator-activated receptor delta protects against obesity-related glomerulopathy through the P38 MAPK pathway. Obesity (Silver Spring) 2013; 21: 538-45.
40. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011; 29: 415-45.
41. Korolczuk A, Dudka J. Increased Risk of Cardiovascular Complications in Chronic Kidney Disease: A Possible Role of Leptin. Curr Pharm Des 2013.
42. Kampoli AM, Tousoulis D, Briasoulis A, Latsios G, Papageorgiou N, Stefanadis C. Potential pathogenic inflammatory mechanisms of endothelial dysfunction induced by type 2 diabetes mellitus. Curr Pharm Des 2011; 17: 4147-58.
43. Xue P, Hou Y, Chen Y, et al. Adipose deficiency of Nrf2 in ob/ob mice results in severe metabolic syndrome. Diabetes 2013; 62: 845-54.
44. Kennedy DJ, Chen Y, Huang W, et al. CD36 and Na/K-ATPasealpha1 form a proinflammatory signaling loop in kidney. Hypertension 2013; 61: 216-24.
45. Jadhav A, Ndisang JF. Heme arginate suppresses cardiac lesions and hypertrophy in deoxycorticosterone acetate-salt hypertension. Exp Biol Med (Maywood) 2009; 234: 764-78.
46. Jadhav A, Ndisang JF. Treatment with heme arginate alleviates adipose tissue inflammation and improves insulin sensitivity and glucose metabolism in a rat model of Human primary aldosteronism. Free Radic Biol Med 2012; 53: 2277-2286.
47. Jadhav A, Torlakovic E, Ndisang JF. Interaction Among Heme Oxygenase, Nuclear Factor-{kappa}B, and Transcription Activating Factors in Cardiac Hypertrophy in Hypertension. Hypertension 2008; 52: 910-917.
48. Jadhav A, Torlakovic E, Ndisang JF. Hemin therapy attenuates kidney injury in deoxycorticosterone acetate-salt hypertensive rats. Am J Physiol Renal Physiol 2009; 296: F521-F534.
49. Ndisang, J. F.; Masini, E.; Mannaioni, P. F.; Wang, R. In Carbon monoxide and cardiovascular functions; Wang R, ed.; CPC Press: Boca Raton, 2002, pp. 165-180.
50. Ndisang JF, Baronti R, Cecere G, Masini E, Bani D, Mannaioni PF. Relaxin generates nitric oxide and provides protection against cardiac anaphylaxis. Inflamm Res 2001; 50 Suppl 2: S122-3.
51. Ndisang JF, Gai P, Berni L, et al. Modulation of the immunological response of guinea pig mast cells by carbon monoxide. Immunopharmacology 1999; 43: 65-73.
52. Ndisang JF, Jadhav A. Up-regulating the hemeoxygenase system enhances insulin sensitivity and improves glucose metabolism in insulin-resistant diabetes in Goto-Kakizaki rats. Endocrinology 2009; 150: 2627-36.
53. Ndisang JF, Jadhav A. Upregulating the heme oxygenase system suppresses left ventricular hypertrophy in adult spontaneously hypertensive rats for 3 months. J Card Fail 2009; 15: 616-28.
54. Ndisang JF, Jadhav A. Heme oxygenase system enhances insulin sensitivity and glucose metabolism in streptozotocin-induced diabetes. Am J Physiol Endocrinol Metab 2009; 296: E829-41.
55. Ndisang JF, Jadhav A. The heme oxygenase system attenuates pancreatic lesions and improves insulin sensitivity and glucose metabolism in deoxycorticosterone acetate hypertension. Am J Physiol Regul Integr Comp Physiol 2010; 298: R211-23.
56. Ndisang JF, Jadhav A. Heme arginate therapy enhanced adiponectin and atrial natriuretic peptide, but abated endothelin-1 with attenuation of kidney histopathological lesions in mineralocorticoid-induced hypertension. J Pharmacol Exp Ther 2010; 334: 87-98.
57. Ndisang JF, Jadhav A. Heme-arginate suppresses phospholipase C and oxidative stress in the mesenteric arterioles of mineralcorticoid-induced hypertensive rats. Hypertens Res 2010; 33: 338-47.
58. Ndisang JF, Jadhav A, Lane N. Interaction between the heme oxygenase system and aldosterone in hypertension. Int J Angiol 2007; 16: 92-97.
59. Ndisang JF, Lane N, Jadhav A. Crosstalk between the heme oxygenase system, aldosterone, and phospholipase C in hypertension. J Hypertens 2008; 26: 1188-99.
60. Ndisang JF, Lane N, Jadhav A. The heme oxygenase system abates hyperglycemia in Zucker diabetic fatty rats by potentiating insulinsensitizing pathways. Endocrinology 2009; 150: 2098-108.
61. Ndisang JF, Lane N, Jadhav A. Upregulation of the heme oxygenase system ameliorates postprandial and fasting hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 2009; 296: E1029-41.
62. Ndisang JF, Lane N, Syed N, Jadhav A. Up-regulating the heme oxygenase system with hemin improves insulin sensitivity and glucose metabolism in adult spontaneously hypertensive rats. Endocrinology 2010; 151: 549-60.
63. Ndisang JF, Mishra M. The Heme Oxygenase System Selectively Suppresses the Proinflammatory Macrophage M1 Phenotype and Potentiates Insulin Signaling in Spontaneously Hypertensive Rats. Am J Hypertens 2013; 26: 1123-31.
64. Ndisang JF, Moncini M, Gai P, et al. Induction of heme oxygenase provides protection against cardiac anaphylaxis. Inflamm Res 2000; 49 Suppl 1: S76-7.
65. Ndisang JF, Tabien HE, Wang R. Carbon monoxide and hypertension. J Hypertens 2004; 22: 1057-74.
66. Ndisang JF, Wang R. Novel therapeutic strategies for impaired endothelium-dependent vascular relaxation. Expert Opin Ther Patents 2002; 12: 1237-1247.
67. Ndisang JF, Wang R. Age-related alterations in soluble guanylyl cyclase and cGMP pathway in spontaneously hypertensive rats. J Hypertens 2003; 21: 1117-24.
68. Ndisang JF, Wang R. Alterations in heme oxygenase/carbon monoxide system in pulmonary arteries in hypertension. Exp Biol Med (Maywood) 2003; 228: 557-63.
69. Ndisang JF, Wang R, Vannacci A, Marzocca C, et al. Haeme oxygenase-1 and cardiac anaphylaxis. Br J Pharmacol 2001; 134: 1689-96.
70. Ndisang JF, Wu L, Zhao W, Wang R. Induction of heme oxygenase-1 and stimulation of cGMP production by hemin in aortic tissues from hypertensive rats. Blood 2003; 101: 3893-900.
71. Ndisang JF, Zhao W, Wang R. Selective regulation of blood pressure by heme oxygenase-1 in hypertension. Hypertension 2002; 40: 315-21.
72. Ndisang JF G, Berni L, Mirabella C, Baronti R, Mannaioni PF, Masini E. Modulation of the immunological response of guinea pig mast cells by carbon monoxide. Immunopharmacology 1999; 43 65-73.
73. Wang Y, Yu Q, Chen Y, Cao F. Pathophysiology and therapeutics of cardiovascular disease in metabolic syndrome. Curr Pharm Des 2013.
74. Carmean CM, Cohen RN, Brady MJ. Systemic regulation of adipose metabolism. Biochim Biophys Acta 2013.
75. Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci 2013; 9: 191-200.
76. Leal Vde O, Mafra D. Adipokines in obesity. Clin Chim Acta 2013; 419: 87-94.
77. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 2012; 18: 363-74.
78. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
79. Sethi JK, Hotamisligil GS. The role of TNF alpha in adipocyte metabolism. Semin Cell Dev Biol 1999; 10: 19-29.
80. Alam I, Ng TP, Larbi A. Does inflammation determine whether obesity is metabolically healthy or unhealthy? The aging perspective. Mediators Inflamm 2012; 2012: 456456.
81. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-15.
82. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95: 2111-9.
83. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expression of TNF alpha by human muscle. Relationship to insulin resistance. J Clin Invest 1996; 97: 1111-6.
84. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-808.
85. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389: 610-4.
86. Arai S, Maehara N, Iwamura Y, et al. Obesity-associated autoantibody production requires AIM to retain the immunoglobulin M immune complex on follicular dendritic cells. Cell Rep 2013; 3: 1187-98.
87. Sharkey D, Gardner DS, Symonds ME, Budge H. Maternal nutrient restriction during early fetal kidney development attenuates the renal innate inflammatory response in obese young adult offspring. Am J Physiol Renal Physiol 2009; 297: F1199-207.
88. Scholtes VP, Versteeg D, de Vries JP, et al. Toll-like receptor 2 and 4 stimulation elicits an enhanced inflammatory response in human obese patients with atherosclerosis. Clin Sci (Lond) 2011; 121: 205-14.
89. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007; 132: 2169-80.
90. Weisberg SP, Hunter D, Huber R, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006; 116: 115-24.
91. Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 2013; 339: 166-72.
92. Despres JP. Abdominal obesity and cardiovascular disease: is inflammation the missing link? Can J Cardiol 2012; 28: 642-52.
93. Tracy RP. Inflammation markers and coronary heart disease. Curr Opin Lipidol 1999; 10: 435-41.
94. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004; 109: II2-10.
95. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
96. Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev 2007; 65: S253-9.
97. Lundvig DM, Immenschuh S, Wagener FA. Heme oxygenase, inflammation, and fibrosis: the good, the bad, and the ugly? Front Pharmacol 2012; 3: 81.
98. Tack CJ, Stienstra R, Joosten LA, Netea MG. Inflammation links excess fat to insulin resistance: the role of the interleukin-1 family. Immunol Rev 2012; 249: 239-52.
99. de Lemos ET, Oliveira J, Pinheiro JP, Reis F. Regular physical exercise as a strategy to improve antioxidant and anti-inflammatory status: benefits in type 2 diabetes mellitus. Oxid Med Cell Longev 2012; 2012: 741545.
100. Winer S, Chan Y, Paltser G, et al. Normalization of obesityassociated insulin resistance through immunotherapy. Nat Med 2009; 15: 921-9.
101. Hirabara SM, Gorjao R, Vinolo MA, Rodrigues AC, Nachbar RT, Curi R. Molecular targets related to inflammation and insulin resistance and potential interventions. J Biomed Biotechnol 2012; 2012: 379024.
102. Abdul-Ghani MA, DeFronzo RA. Pathogenesis of insulin resistance in skeletal muscle. J Biomed Biotechnol 2010; 2010: 476279.
103. Kontrogianni-Konstantopoulos A, Benian G, Granzier H. Advances in muscle physiology and pathophysiology. J Biomed Biotechnol 2010; 2010.
104. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454: 428-35.
105. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-6.
106. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010; 72: 219-46.
107. Ito A, Suganami T, Yamauchi A, et al. Role of CC chemokine receptor 2 in bone marrow cells in the recruitment of macrophages into obese adipose tissue. J Biol Chem 2008; 283: 35715-23.
108. Kolb H, Mandrup-Poulsen T. The global diabetes epidemic as a consequence of lifestyle-induced low-grade inflammation. Diabetologia 2010; 53: 10-20.
109. Heitmann BL, Westerterp KR, Loos RJ, et al. Obesity: lessons from evolution and the environment. Obes Rev 2012; 13: 910-22.
110. Alegria-Torres JA, Baccarelli A, Bollati V. Epigenetics and lifestyle. Epigenomics 2011; 3: 267-77.
111. Kempf K, Rathmann W, Herder C. Impaired glucose regulation and type 2 diabetes in children and adolescents. Diabetes Metab Res Rev 2008; 24: 427-37.
112. Berends LM, Ozanne SE. Early determinants of type-2 diabetes. Best Pract Res Clin Endocrinol Metab 2012; 26: 569-80.
113. Eckel RH. Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1997; 96: 3248-50.
114. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006; 113: 898-918.
115. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005; 46: e1-82.
116. Rabkin SW, Mathewson FA, Hsu PH. Relation of body weight to development of ischemic heart disease in a cohort of young North American men after a 26 year observation period: the Manitoba Study. Am J Cardiol 1977; 39: 452-8.
117. Baena-Diez JM, Byram AO, Grau M, et al. Obesity is an independent risk factor for heart failure: Zona Franca Cohort study. Clin Cardiol 2010; 33: 760-4.
118. Dela Cruz CS, Matthay RA. Role of obesity in cardiomyopathy and pulmonary hypertension. Clin Chest Med 2009; 30: 509-23, ix.
119. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 968-77.
120. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305-13.
121. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009; 53: 1925-32.
122. Lavie CJ, Milani RV, Ventura HO, Cardenas GA, Mehra MR, Messerli FH. Disparate effects of left ventricular geometry and obesity on mortality in patients with preserved left ventricular ejection fraction. Am J Cardiol 2007; 100: 1460-4.
123. Karason K, Wallentin I, Larsson B, Sjostrom L. Effects of obesity and weight loss on left ventricular mass and relative wall thickness: survey and intervention study. BMJ 1997; 315: 912-6.
124. Alaud-din A, Meterissian S, Lisbona R, MacLean LD, Forse RA. Assessment of cardiac function in patients who were morbidly obese. Surgery 1990; 108: 809-18; discussion 818-20.
125. Alpert MA. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci 2001; 321: 225-36.
126. Lavie CJ, Amodeo C, Ventura HO, Messerli FH. Left atrial abnormalities indicating diastolic ventricular dysfunction in cardiopathy of obesity. Chest 1987; 92: 1042-6.
127. Mizushige K, Yao L, Noma T, et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulinresistant prediabetic stage of a type II diabetic rat model. Circulation 2000; 101: 899-907.
128. Messerli FH. Cardiovascular effects of obesity and hypertension. Lancet 1982; 1: 1165-8.
129. Messerli FH, Aepfelbacher FC. Hypertension and left-ventricular hypertrophy. Cardiol Clin 1995; 13: 549-57.
130. Duflou J, Virmani R, Rabin I, Burke A, Farb A, Smialek J. Sudden death as a result of heart disease in morbid obesity. Am Heart J 1995; 130: 306-13.
131. Malavazos AE, Ermetici F, Coman C, Corsi MM, Morricone L, Ambrosi B. Influence of epicardial adipose tissue and adipocytokine levels on cardiac abnormalities in visceral obesity. Int J Cardiol 2007; 121: 132-4.
132. Alpert MA, Lambert CR, Panayiotou H, et al. Relation of duration of morbid obesity to left ventricular mass, systolic function, and diastolic filling, and effect of weight loss. Am J Cardiol 1995; 76: 1194-7.
133. Licata G, Scaglione R, Paterna S, et al. Left ventricular function response to exercise in normotensive obese subjects: influence of degree and duration of obesity. Int J Cardiol 1992; 37: 223-30.
134. Messerli FH, Ventura HO, Reisin E, et al. Borderline hypertension and obesity: two prehypertensive states with elevated cardiac output. Circulation 1982; 66: 55-60.
135. Matsuzawa Y. Establishment of a concept of visceral fat syndrome and discovery of adiponectin. Proc Jpn Acad Ser B Phys Biol Sci 2010; 86: 131-41.
136. Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol 2008; 52: 1201-10.
137. Johnson AR, Milner JJ, Makowski L. The inflammation highway: metabolism accelerates inflammatory traffic in obesity. Immunol Rev 2012; 249: 218-38.
138. Scarpace PJ, Zhang Y. Leptin resistance: a prediposing factor for diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 2009; 296: R493-500.
139. Enriori PJ, Evans AE, Sinnayah P, Cowley MA. Leptin resistance and obesity. Obesity (Silver Spring) 2006; 14 Suppl 5: 254S-258S.
140. Romero-Corral A, Sierra-Johnson J, Lopez-Jimenez F, et al. Relationships between leptin and C-reactive protein with cardiovascular disease in the adult general population. Nat Clin Pract Cardiovasc Med 2008; 5: 418-25.
141. Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005; 436: 356-62.
142. Kalupahana NS, Massiera F, Quignard-Boulange A, et al. Overproduction of angiotensinogen from adipose tissue induces adipose inflammation, glucose intolerance, and insulin resistance. Obesity (Silver Spring) 2012; 20: 48-56.
143. Fesus G, Dubrovska G, Gorzelniak K, et al. Adiponectin is a novel humoral vasodilator. Cardiovasc Res 2007; 75: 719-27.
144. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007; 380: 24-30.
145. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-6.
146. Deng G, Long Y, Yu YR, Li MR. Adiponectin directly improves endothelial dysfunction in obese rats through the AMPK-eNOS Pathway. Int J Obes (Lond) 2010; 34: 165-71.
147. Yilmaz MI, Sonmez A, Caglar K, et al. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton) 2007; 12: 147-53.
148. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
149. Calabro P, Chang DW, Willerson JT, Yeh ET. Release of Creactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol 2005; 46: 1112-3.
150. Han CY, Subramanian S, Chan CK, et al. Adipocyte-derived serum amyloid A3 and hyaluronan play a role in monocyte recruitment and adhesion. Diabetes 2007; 56: 2260-73.
151. Mertens I, Verrijken A, Michiels JJ, et al. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond) 2006; 30: 1308-14.
152. Fain JN. Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review. Mediators Inflamm 2010; 2010: 513948.
153. McGavock JM, Victor RG, Unger RH, Szczepaniak LS. Adiposity of the heart, revisited. Ann Intern Med 2006; 144: 517-24.
154. Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003; 144: 5159-65.
155. Montani JP, Carroll JF, Dwyer TM, et al. Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases. Int J Obes Relat Metab Disord 2004; 28 Suppl 4: S58-65.
156. Yehuda-Shnaidman E, Schwartz B. Mechanisms linking obesity, inflammation and altered metabolism to colon carcinogenesis. Obes Rev 2012; 13: 1083-95.
157. Feraco A, Armani A, Mammi C, Fabbri A, Rosano GM, Caprio M. Role of mineralocorticoid receptor and renin-angiotensinaldosterone system in adipocyte dysfunction and obesity. J Steroid Biochem Mol Biol 2013.
158. Thethi T, Kamiyama M, Kobori H. The link between the reninangiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome. Curr Hypertens Rep 2012; 14: 160-9.
159. Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue reninangiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol 2003; 35: 807-25.
160. Giacchetti G, Faloia E, Mariniello B, et al. Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hypertens 2002; 15: 381-8.
161. Whaley-Connell A, Sowers JR. Oxidative stress in the cardiorenal metabolic syndrome. Curr Hypertens Rep 2012; 14: 360-5.
162. Goodfriend TL, Egan BM, Kelley DE. Aldosterone in obesity. Endocr Res 1998; 24: 789-96.
163. Frederich RC, Jr., Kahn BB, Peach MJ, Flier JS. Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension 1992; 19: 339-44.
164. Hainault I, Nebout G, Turban S, Ardouin B, Ferre P, Quignard-Boulange A. Adipose tissue-specific increase in angiotensinogen expression and secretion in the obese (fa/fa) Zucker rat. Am J Physiol Endocrinol Metab 2002; 282: E59-66.
165. Van Harmelen V, Ariapart P, Hoffstedt J, Lundkvist I, Bringman S, Arner P. Increased adipose angiotensinogen gene expression in human obesity. Obes Res 2000; 8: 337-41.
166. Weiland F, Verspohl EJ. Variety of angiotensin receptors in 3T3-L1 preadipose cells and differentiated adipocytes. Horm Metab Res 2008; 40: 760-6.
167. Crandall DL, Armellino DC, Busler DE, McHendry-Rinde B, Kral JG. Angiotensin II receptors in human preadipocytes: role in cell cycle regulation. Endocrinology 1999; 140: 154-8.
168. Massiera F, Seydoux J, Geloen A, et al. Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology 2001; 142: 5220-5.
169. Yvan-Charvet L, Even P, Bloch-Faure M, et al. Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes 2005; 54: 991-9.
170. Kouyama R, Suganami T, Nishida J, et al. Attenuation of dietinduced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology 2005; 146: 3481-9.
171. Aghamohammadzadeh R, Heagerty AM. Obesity-related hypertension: epidemiology, pathophysiology, treatments, and the contribution of perivascular adipose tissue. Ann Med 2012; 44 Suppl 1: S74-84.
172. Stankevicius E, Kevelaitis E, Vainorius E, Simonsen U. [Role of nitric oxide and other endothelium-derived factors]. Medicina (Kaunas) 2003; 39: 333-41.
173. Gross SS, Wolin MS. Nitric oxide: pathophysiological mechanisms. Annu Rev Physiol 1995; 57: 737-69.
174. Yudkin JS, Eringa E, Stehouwer CD. "Vasocrine" signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 2005; 365: 1817-20.
175. Maier JA. Endothelial cells and magnesium: implications in atherosclerosis. Clin Sci (Lond) 2012; 122: 397-407.
176. Vanhoutte PM. Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circ J 2009; 73: 595-601.
177. Kopple JD. Obesity and chronic kidney disease. J Ren Nutr 2010; 20: S29-30.
178. Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Garcia-Perez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 2011; 7: 327-40.
179. Navarro-Gonzalez JF, Mora-Fernandez C. Inflammatory pathways. Contrib Nephrol 2011; 170: 113-23.
180. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498-509.
181. Adelman RD, Restaino IG, Alon US, Blowey DL. Proteinuria and focal segmental glomerulosclerosis in severely obese adolescents. J Pediatr 2001; 138: 481-5.
182. Mezzano S, Aros C, Droguett A, et al. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 2004; 19: 2505-12.
183. Eknoyan G. Obesity, diabetes, and chronic kidney disease. Curr Diab Rep 2007; 7: 449-53.
184. Ford ES, Zhao G, Li C, Pearson WS, Mokdad AH. Trends in obesity and abdominal obesity among hypertensive and nonhypertensive adults in the United States. Am J Hypertens 2008; 21: 1124-8.
185. Hall JE. Mechanisms of abnormal renal sodium handling in obesity hypertension. Am J Hypertens 1997; 10: 49S-55S.
186. Bayliss G, Weinrauch LA, D'Elia JA. Pathophysiology of obesityrelated renal dysfunction contributes to diabetic nephropathy. Curr Diab Rep 2012; 12: 440-6.
187. Maddox DA, Alavi FK, Santella RN, Zawada ET, Jr. Prevention of obesity-linked renal disease: age-dependent effects of dietary food restriction. Kidney Int 2002; 62: 208-19.
188. Chagnac A, Herman M, Zingerman B, et al. Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption. Nephrol Dial Transplant 2008; 23: 3946-52.
189. Engeli S, Bohnke J, Gorzelniak K, et al. Weight loss and the reninangiotensin-aldosterone system. Hypertension 2005; 45: 356-62.
190. Morales E, Valero MA, Leon M, Hernandez E, Praga M. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003; 41: 319-27.
191. Montani JP, Antic V, Yang Z, Dulloo A. Pathways from obesity to hypertension: from the perspective of a vicious triangle. Int J Obes Relat Metab Disord 2002; 26 Suppl 2: S28-38.
192. Hall JE, Henegar JR, Dwyer TM, et al. Is obesity a major cause of chronic kidney disease? Adv Ren Replace Ther 2004; 11: 41-54.
193. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension 2006; 47: 312-8.
194. Brown NJ. Aldosterone and vascular inflammation. Hypertension 2008; 51: 161-7.
195. Wei Y, Whaley-Connell AT, Habibi J, et al. Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation. Hypertension 2009; 53: 158-65.
196. Stas S, Whaley-Connell A, Habibi J, et al. Mineralocorticoid receptor blockade attenuates chronic overexpression of the reninangiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology 2007; 148: 3773-80.
197. Whaley-Connell A, Habibi J, Wei Y, et al. Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. Am J Physiol Renal Physiol 2009; 296: F1013-22.
198. Kamijo A, Kimura K, Sugaya T, et al. Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage. Kidney Int 2002; 62: 1628-37.
199. Sarafidis PA, Bakris GL. Non-esterified fatty acids and blood pressure elevation: a mechanism for hypertension in subjects with obesity/insulin resistance? J Hum Hypertens 2007; 21: 12-9.
200. Sarafidis PA. Obesity, insulin resistance and kidney disease risk: insights into the relationship. Curr Opin Nephrol Hypertens 2008; 17: 450-6.
201. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003; 112: 1785-8.
202. Malik VS, Willett WC, Hu FB. Global obesity: trends, risk factors and policy implications. Nat Rev Endocrinol 2013; 9: 13-27.
203. Han JC, Lawlor DA, Kimm SY. Childhood obesity. Lancet 2010; 375: 1737-48.